What is SIGA Technologies?
SIGA Technologies, Inc. is a U.S.-based entity dedicated to developing and commercializing solutions for unmet medical needs and biothreats. The company's flagship product is TPOXX, an orally administered antiviral drug specifically designed for the treatment of orthopoxvirus infections. Established in 1995 and headquartered in New York, SIGA Technologies operates within the biopharmaceutical sector, focusing on public health security and the development of countermeasures against biological threats.
How much funding has SIGA Technologies raised?
SIGA Technologies has raised a total of $12.5M across 1 funding round:
Stock Offering
$12.5M
Stock Issuance/Offering (1997): $12.5M, investors not publicly disclosed
What's next for SIGA Technologies?
The recent major strategic investment positions SIGA Technologies for accelerated growth and expanded market penetration. This capital injection is expected to fuel further research and development, enhance manufacturing capabilities for TPOXX, and support broader commercialization strategies. The company's focus on biothreats and antiviral solutions places it in a critical niche, with potential for significant impact on public health preparedness and response. Future endeavors will likely involve navigating regulatory pathways and securing further partnerships to solidify its market presence.
See full SIGA Technologies company page
